Reports Q3 revenue $0, consensus $56.92M. Aggregate cash and cash equivalents and short-term investments were $238.6M and $412.3M at September 30, 2025 and December 31, 2024, respectively.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Ivonescimab’s Promising Trial Results Reinforce Buy Rating for Summit Therapeutics
- Summit Therapeutics price target raised to $40 from $35 at Citi
- Summit announces ivonescimab, chemo showed improvement in primary endpoint
- Summit Therapeutics PLC (SMMT) Q3 Earnings Cheat Sheet
- Summit Therapeutics announces expansion of Phase III program of ivonescimab